Angle
Angle Acquires Option to License NuProbe Pan-Cancer NGS Panel
Angle said the panel would help advance its efforts to develop a liquid biopsy assay for circulating tumor cells and ctDNA.
Angle Raises $630K in Open Offer of Shares
The company said the proceeds will strengthen its balance sheet as it works to advance its circulating tumor cell platform for diagnostics and drug development.
Angle to Develop Prostate Cancer Liquid Biopsy Assay for AstraZeneca
The company will use its Parsortix platform to develop a circulating tumor cell-based assay to measure androgen receptor status in therapy response.
Angle Inks Assay Development Deal with AstraZeneca
The company is working to tailor its existing circulating tumor cell DNA damage response assay for use in pharmaceutical R&D.
Angle, BioView Partner to Develop Quantitative HER2 Assay Using Circulating Tumor Cells
The companies said recent developments in HER2-targeted therapies have created new commercial opportunities for a blood-based test.